Call for EU allergy research via FP7

9 April 2006

The European Parliament rapporteur on the European Union's seventh framework research program (FP7), Jerzy Buzek, wants the inclusion of allergic diseases under the general health thematic research in the future FP7. In the current European Commission proposal for FP7, allergies figure only under the food thematic research.

Allergies result from complex interactions between genes and environment. Allergic diseases have dramatically in-creased since 1950 due to a number of different factors: greater exposure to allergens, pollutants, dietary changes, food-processing techniques, housing architecture and the water supply. Currently, nearly one-third of children are allergic and 30%-50% of them develop asthma.

"Allergies have a huge negative impact on health, quality of life, education and career achievement and thus present a major health economic burden for the EU," said Anthony Frew, president of the Stockholm, Sweden-based European Academy of Allergology and Clinical Immunology, at a debate organized by Dr Buzek recently, in Brussels.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight